About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Second Window Indocyanine Green for All Nervous System Tumors

NCT05746104·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Abramson Cancer Center at Penn Medicine

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Adult patients 18 years of age and older
2. Patients presenting with a nervous system tumor presumed to be resectable and at risk for local recurrence on pre-operative assessment
3. Good operative candidates, as determined by the treating physician and multidisciplinary team
4. Subjects capable of giving informed consent

You may not be if

1. Pregnant women, as determined by urinary or serum beta hCG within 48 hours of surgery
2. Subjects with a history of iodide allergies
3. Vulnerable patient populations
4. Patients unable to participate in the consent process
5. Patients with history of uncontrolled HTN (requiring ER admission or ≥ 3 BP medications)

The record

StatusEnrolling by invitation

PhasePhase 1

Taking part105

StartedMar 2023

UpdatedJan 22, 2026

Conditions

Nervous System Tumor

Where1

Pennsylvania Hospital
Philadelphia, Pennsylvania, United States

Clareo Health | Second Window Indocyanine Green for All Nervous System Tumors